43 results on '"Kletzel, Morris"'
Search Results
2. Veno-occlusive disease after high-dose busulfan–melphalan in neuroblastoma
3. SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery
4. Immune reconstitution and survival of 100 SCID patients post–hematopoietic cell transplant: a PIDTC natural history study
5. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age
6. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis
7. Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation
8. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia
9. Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation
10. 116 - Event Free Survival in Severe Combined Immune Deficiency (SCID) Infants after Conditioned Umbilical Cord Blood Transplantation (UCBT) Benefits from Omitting Serotherapy
11. Early mixed T‐cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant
12. Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants
13. The Impact of High-resolution HLA-A, HLA-B, HLA-C, and HLA-DRB1 on Transplant-related Outcomes in Single-unit Umbilical Cord Blood Transplantation in Pediatric Patients
14. Reduced‐toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high‐risk hematologic malignancies.
15. Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease
16. 460 - Health Related and Functional Outcomes for Infants Diagnosed with High Risk Acute Lymphoblastic Leukemia (ALL) Prior to Six Months of Age Who Undergo a Single Allogeneic Hematopoietic Progenitor Cell Transplant (HPCT) with a Total Body Irradiation (TBI) Conditioning Regimen Prior to Two Years of Age
17. Reduced Toxicity, Myeloablative Conditioning Regimen with Busulfan, Fludarabine, Anti-Thymocyte Globulin and 400 Cgy TBI in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant for High-Risk Hematologic Malignancies
18. Early Hematopoietic Cell Transplant (HCT) Outcomes of Children with Severe Combined Immunodeficiency Disease (SCID): The First Seventy Four Patients of the Primary Immune Deficiency Treatment Consortium (PIDTC) Prospective Study 6901
19. Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia in the Northstar (HGB-204) Study
20. 62 - Safety Following Autologous Transplantation with Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) in the Northstar Hgb-204 Study
21. High-dose chemotherapy and autologous hematopoietic stem-cell rescue for treatment of relapsed and refractory Wilms tumor: Re-evaluating outcomes.
22. Clinical Outcomes up to 3 Years Following Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia in the Northstar Hgb-204 Study
23. 104 - Genotype, Phenotype and T Cell Counts at One Year Predict Survival and Long Term Immune Reconstitution after Transplantation in Severe Combined Immune Deficiency (SCID)—The Primary Immune Deficiency Treatment Consortium (PIDTC)
24. Epidemiology and Antibiotic Resistance Patterns of Bacterial Bloodstream Infection Post Allogeneic Hematopoietic Progenitor Cell Transplant – Single Pediatric Center Experience
25. Maintaining a Successful Quality Management Program: Fifteen Years of Experience at a Single Institution
26. Fecal Calprotectin – a Useful Tool to Predict Steroid Responsiveness of Gastrointestinal Acute Graft-Versus-Host Disease
27. Does Partial Donor Chimerism (PDC) Increase the Risk of Relapse in Pediatric Patients with Leukemia Undergoing Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplant (HSCT)
28. Significant, Transient Growth Delays in Children after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplant (RIC-HSCT) for Primary Immunodeficiency
29. Potential Impact of Bacterial Bloodstream Infection (BSI) on Outcomes of Allogeneic Hematopoietic Progenitor Cell Transplant – Single Pediatric Center Experience
30. Poor T Cell Reconstitution at 100 Days after T Cell-Replete Hematopoietic Cell Transplantation (HCT) for SCID Is Associated with Later Risk of Death or Need for 2nd Transplant in the 6901 Prospective Study of the Pidtc
31. Late Cardiovascular Morbidity Following Pediatric Allogeneic Hematopoietic Cell Transplantation
32. Survival and Late Effects of Children Undergoing Myeloablative Allogeneic HCT at Less Than Three Years of Age: A Report from the Center for International Blood and Marrow Transplant Research
33. Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy.
34. Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product)
35. Overall Survival (OS) of Pediatric Patients with Moderate to Severe Chronic Graft Vs. Host Disease (CGVHD). a Single Institution Experience
36. Predicting Relapse Post-Hematopoietic Stem Cell Transplant for Pediatric AML and MDS
37. Incidence and Risk Factors for Metabolic Syndrome in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients-a Tertiary Care Center Experience
38. Studying the Optimal Intravenous Busulfan Exposure in Pediatric Allogeneic Hematopoietic Cell Transplantation (alloHCT) to Improve Clinical Outcomes: A Multicenter Study
39. Robust Immune Reconstitution in Children with Severe Primary Immunodeficiency after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation
40. Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression.
41. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
42. Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy.
43. Expression of Wilms tumor gene in high risk neuroblastoma: complementary marker to tyrosine hydroxylase for detection of minimal residual disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.